logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2016
Corbus Pharmaceuticals Holdings, Inc.
Topline data from phase 2 Study of Resunab
Cystic Fibrosis
Q4 2016
MediciNova Inc
Interim efficacy analysis of Phase 2b Trial of MN-166
Progressive multiple sclerosis
Q4 2016
Heat Biologics Inc.
Topline data from Phase 2 trial of HS-410
High-risk, non-muscle invasive bladder cancer
Q4 2016
Heat Biologics Inc.
Topline data from Phase 1b trial of HS-110 plus a PD-1 checkpoint inhibitor
Non-small cell lung cancer
Q4 2016
Aclaris Therapeutics
Results from 2 phase 3 pivotal trials of A-101 Topical Solution
Seborrheic keratosis
Q4 2016
INOTEK PHARMACEUTICALS CORP
Topline data from 1st Phase 3 trial of Trabodenoson (MATrX-1)
Primary open-angle glaucoma or ocular hypertension
Q4 2016
Cerecor Inc.
Data from phase 2 study of CERC-501
Smoking cessation
Q4 2016
Voyager Therapeutics
Data from phase 1b trial of VY-AADC01
Advanced Parkinson’s disease
Q4 2016
Halozyme Therapeutics, Inc.
Mature PFS data, overall response rate from phase 2 trial of PEGPH20
Metastatic pancreatic cancer.
Q4 2016
Tenax Therapeutics Inc
Topline data from phase 3 trial of Levosimendan (LEVO-CTS)
Low cardiac output syndrome
Early Q4 2016
Opexa Therapeutics Inc.
Topline data from phase 2b study of Tcelna ( Abili-T )
Secondary progressive MS.
Q4 2016
Anthera Pharmaceuticals, Inc.
Topline data from phase 3 study of Sollpura (SOLUTION)
For patients with cystic fibrosis who suffer from exocrine pancreatic insufficiency
Q4 2016
Flexion Therapeutics, Inc.
NDA submission of Zilretta
Osteoarthritis of the knee
Q4 2016
Arbutus Biopharma Corp.
HBsAg reduction data from multiple dose portion of phase II trial of ARB-1467
Hepatitis B virus infection
01-Oct-2016 To 31-Mar-2017
Cynapsus Therapeutics
Topline data from phase 3 safety study of APL-130277(CTH-301)
OFF episodes associated with Parkinson’s
Q4 2016
Xenon Pharmaceuticals Inc.
Results from phase 2 Trial of XEN801
Moderate to Severe Acne
Q4 2016
Halozyme Therapeutics, Inc.
PFS data from phase 2 study of PEGPH20 ( HALO-202)
Metastatic pancreatic cancer
01-Oct-2016 To 31-Mar-2017
Puma Biotechnology Inc.
Data from phase III trial of Neratinib
Third-line HER2-positive metastatic breast cancer
Q4 2016
Puma Biotechnology Inc.
Data from phase II trial of Neratinib
Metastatic breast cancer patients with brain metastases
Q4 2016
Puma Biotechnology Inc.
Data from phase II trial of Neratinib & Fulvestrant
HER2 non-amplified breast cancer that has a HER2 mutation
Late Q4 2016
Recro Pharma Inc.
Topline data from phase 3 trial of IV Meloxicam
Abdominoplasty Surgery
Q4 2016
Achillion Pharmaceuticals Inc.
Interim results from phase 2 trial of ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Q4 2016
Synergy Pharmaceuticals, Inc.
Topline data from first phase 3 study of Plecanatide
Irritable Bowel Syndrome with Constipation (IBS-C)
Q4 2016
Synergy Pharmaceuticals, Inc.
Topline results from 2nd phase 3 study of Plecanatide
Irritable Bowel Syndrome with Constipation (IBS-C)
Q4 2016
Tesaro Inc.
NDA submission for Niraparib
Ovarian cancer